Avelumab and Merkel Cell Carcinoma: Long-Term Outcomes and Occupational Exposure Considerations

From General Health Information to Targeted Oncology Communication

General health and science communication has long emphasized the importance of informed decision-making regarding medical treatments and disease prevention. In this tradition, public health messaging has evolved to address both broad wellness principles and specific therapeutic interventions, particularly as novel biologics enter clinical practice. The legacy of such communication lies in translating complex biomedical advances into actionable knowledge for diverse audiences, balancing hope with realistic expectations. This foundational approach now extends to the domain of oncology, where targeted immunotherapies such as Avelumab have become central to managing certain malignancies. Avelumab, a PD-L1 inhibitor, is approved for the treatment of Merkel cell carcinoma, a rare but aggressive skin cancer. As clinical experience accumulates, attention has turned to understanding long-term outcomes following exposure to this agent. While the therapeutic benefits are well documented, the occupational context introduces a distinct layer of concern. Healthcare workers, laboratory personnel, and pharmaceutical manufacturing staff may encounter Avelumab during preparation, administration, or disposal. Unlike patients who receive the drug under controlled conditions for therapeutic intent, occupational exposure is inadvertent and may involve repeated low-level contact. This shift from a patient-centered therapeutic narrative to an occupational safety perspective requires careful consideration of risk assessment, monitoring protocols, and protective measures. The transition from general health information to this specific exposure concern underscores the need for targeted guidance that addresses both clinical efficacy and workplace safety.

Clinical Evidence and Therapeutic Context of Avelumab in Merkel Cell Carcinoma

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), making it the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). MCC is a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis, associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). The approval of avelumab for metastatic MCC was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200. In Part A of that study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibition, including with avelumab, has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, emerging evidence suggests that combined therapy with ipilimumab and nivolumab may offer benefit in avelumab-refractory MCC. In a retrospective study conducted at three academic sites in Germany, clinical and molecular data from five patients with metastatic MCC refractory to avelumab who were subsequently treated with combined ipilimumab plus nivolumab were evaluated. Three out of five patients responded to this combination according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG similarly reported that ipilimumab plus nivolumab can be effective in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study confirmed that immune checkpoint inhibitors, including avelumab and pembrolizumab, are approved for advanced MCC, but noted that about half of patients progress on initial ICI therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Adverse Effects and Risk Considerations in Avelumab Therapy

Regarding adverse effects, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab. The hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the potential for avelumab to trigger or reactivate underlying granulomatous diseases, which should be considered in the risk assessment for patients receiving this therapy. The adequacy of warnings regarding avelumab and MCC is supported by the drug's approval status and the clinical trial data that informed its labeling. However, the risk of progression in approximately 50% of patients and the limited options for avelumab-refractory disease underscore the need for ongoing monitoring and further research into salvage therapies. The timeline between avelumab exposure and documented harm, such as immune-related adverse events, can vary; in the reported sarcoidosis case, hypercalcaemia developed during treatment and resolved with intervention, allowing continuation of therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). For prognosis-related considerations, patients who respond to avelumab may experience durable responses, but those who progress face a poor prognosis, with emerging combination therapies offering potential benefit in the refractory setting. In summary, avelumab represents a significant therapeutic advance for metastatic MCC, with a confirmed response rate of about one-third in chemotherapy-refractory patients. However, the high rate of primary or acquired resistance, the potential for immune-related adverse events, and the aggressive nature of MCC necessitate careful patient selection, monitoring, and consideration of subsequent treatment options such as ipilimumab plus nivolumab for refractory cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Avelumab and how does it work in Merkel cell carcinoma?

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) and works by blocking PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells.

What are the long-term outcomes for patients with Merkel cell carcinoma treated with Avelumab?

Long-term outcomes vary: approximately one-third of chemotherapy-refractory patients achieve objective responses, and response rates to PD-1/PD-L1 inhibition can reach up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, about 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who respond, durable responses are possible, but refractory disease carries a poor prognosis. Emerging combination therapies like ipilimumab plus nivolumab may offer benefit in avelumab-refractory cases (https://pubmed.ncbi.nlm.nih.gov/33439294/).

What are the potential adverse effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported events include hypercalcaemia secondary to reactivation of sarcoidosis, which can be managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs may involve the skin, gastrointestinal tract, liver, lungs, and endocrine organs. Monitoring and prompt management are essential.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.